Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis

Minoru Nakamura, Yuki Shimizu-Yoshida, Yasushi Takii, Atsumasa Komori, Terufumi Yokoyama, Toshihito Ueki, Manabu Daikoku, Koji Yano, Takehiro Matsumoto, Kiyoshi Migita, Hiroshi Yatsuhashi, Masahiro Ito, Naohiko Masaki, Hiroshi Adachi, Yukio Watanabe, Yoko Nakamura, Takeo Saoshiro, Takeshi Sodeyama, Michiaki Koga, Shinji ShimodaHiromi Ishibashi

研究成果: ジャーナルへの寄稿記事

88 引用 (Scopus)

抄録

Background/Aims: The presence of antibodies to the 210-kDa glycoprotein of the nuclear pore complex (gp210) is highly indicative of primary biliary cirrhosis (PBC). However, the significance of anti-gp210 antibody titers for monitoring PBC remains unresolved. Methods: We used an ELISA with a gp210 C-terminal peptide as an antigen to assess serum antibody titers in 71 patients with PBC. Results: Patients were classified into three groups: Group A in whom anti-gp210 titers were sustained at a high level, Group B in whom anti-gp210 status changed from positive to negative under ursodeoxycholic acid (UDCA) therapy, Group C in whom anti-gp210 antibodies were negative at the time of diagnosis. The rate of progression to end-stage hepatic failure was significantly higher in group A (60%) as compared to groups B (0%) and C (4.2%). The sustained antibody response to gp210 was closely associated with the severity of interface hepatitis. The significance of anti-gp210 antibody was confirmed by National Hospital Organization Study Group for Liver Disease in Japan. Conclusions: The serial quantitation of serum anti-gp210-C-terminal peptide antibodies is useful for monitoring the effect of UDCA and for the early identification of patients at high risk for end-stage hepatic failure.

元の言語英語
ページ(範囲)386-392
ページ数7
ジャーナルJournal of Hepatology
42
発行部数3
DOI
出版物ステータス出版済み - 3 2005

Fingerprint

Biliary Liver Cirrhosis
Ursodeoxycholic Acid
Anti-Idiotypic Antibodies
Liver Failure
Peptides
Antibodies
Nuclear Pore
Group Psychotherapy
Serum
Hepatitis
Antibody Formation
Liver Diseases
Glycoproteins
Japan
Enzyme-Linked Immunosorbent Assay
Antigens

All Science Journal Classification (ASJC) codes

  • Hepatology

これを引用

Nakamura, M., Shimizu-Yoshida, Y., Takii, Y., Komori, A., Yokoyama, T., Ueki, T., ... Ishibashi, H. (2005). Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. Journal of Hepatology, 42(3), 386-392. https://doi.org/10.1016/j.jhep.2004.11.016

Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. / Nakamura, Minoru; Shimizu-Yoshida, Yuki; Takii, Yasushi; Komori, Atsumasa; Yokoyama, Terufumi; Ueki, Toshihito; Daikoku, Manabu; Yano, Koji; Matsumoto, Takehiro; Migita, Kiyoshi; Yatsuhashi, Hiroshi; Ito, Masahiro; Masaki, Naohiko; Adachi, Hiroshi; Watanabe, Yukio; Nakamura, Yoko; Saoshiro, Takeo; Sodeyama, Takeshi; Koga, Michiaki; Shimoda, Shinji; Ishibashi, Hiromi.

:: Journal of Hepatology, 巻 42, 番号 3, 03.2005, p. 386-392.

研究成果: ジャーナルへの寄稿記事

Nakamura, M, Shimizu-Yoshida, Y, Takii, Y, Komori, A, Yokoyama, T, Ueki, T, Daikoku, M, Yano, K, Matsumoto, T, Migita, K, Yatsuhashi, H, Ito, M, Masaki, N, Adachi, H, Watanabe, Y, Nakamura, Y, Saoshiro, T, Sodeyama, T, Koga, M, Shimoda, S & Ishibashi, H 2005, 'Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis', Journal of Hepatology, 巻. 42, 番号 3, pp. 386-392. https://doi.org/10.1016/j.jhep.2004.11.016
Nakamura, Minoru ; Shimizu-Yoshida, Yuki ; Takii, Yasushi ; Komori, Atsumasa ; Yokoyama, Terufumi ; Ueki, Toshihito ; Daikoku, Manabu ; Yano, Koji ; Matsumoto, Takehiro ; Migita, Kiyoshi ; Yatsuhashi, Hiroshi ; Ito, Masahiro ; Masaki, Naohiko ; Adachi, Hiroshi ; Watanabe, Yukio ; Nakamura, Yoko ; Saoshiro, Takeo ; Sodeyama, Takeshi ; Koga, Michiaki ; Shimoda, Shinji ; Ishibashi, Hiromi. / Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. :: Journal of Hepatology. 2005 ; 巻 42, 番号 3. pp. 386-392.
@article{a34f25eab3c44905b5f1f21de5e69a96,
title = "Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis",
abstract = "Background/Aims: The presence of antibodies to the 210-kDa glycoprotein of the nuclear pore complex (gp210) is highly indicative of primary biliary cirrhosis (PBC). However, the significance of anti-gp210 antibody titers for monitoring PBC remains unresolved. Methods: We used an ELISA with a gp210 C-terminal peptide as an antigen to assess serum antibody titers in 71 patients with PBC. Results: Patients were classified into three groups: Group A in whom anti-gp210 titers were sustained at a high level, Group B in whom anti-gp210 status changed from positive to negative under ursodeoxycholic acid (UDCA) therapy, Group C in whom anti-gp210 antibodies were negative at the time of diagnosis. The rate of progression to end-stage hepatic failure was significantly higher in group A (60{\%}) as compared to groups B (0{\%}) and C (4.2{\%}). The sustained antibody response to gp210 was closely associated with the severity of interface hepatitis. The significance of anti-gp210 antibody was confirmed by National Hospital Organization Study Group for Liver Disease in Japan. Conclusions: The serial quantitation of serum anti-gp210-C-terminal peptide antibodies is useful for monitoring the effect of UDCA and for the early identification of patients at high risk for end-stage hepatic failure.",
author = "Minoru Nakamura and Yuki Shimizu-Yoshida and Yasushi Takii and Atsumasa Komori and Terufumi Yokoyama and Toshihito Ueki and Manabu Daikoku and Koji Yano and Takehiro Matsumoto and Kiyoshi Migita and Hiroshi Yatsuhashi and Masahiro Ito and Naohiko Masaki and Hiroshi Adachi and Yukio Watanabe and Yoko Nakamura and Takeo Saoshiro and Takeshi Sodeyama and Michiaki Koga and Shinji Shimoda and Hiromi Ishibashi",
year = "2005",
month = "3",
doi = "10.1016/j.jhep.2004.11.016",
language = "English",
volume = "42",
pages = "386--392",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis

AU - Nakamura, Minoru

AU - Shimizu-Yoshida, Yuki

AU - Takii, Yasushi

AU - Komori, Atsumasa

AU - Yokoyama, Terufumi

AU - Ueki, Toshihito

AU - Daikoku, Manabu

AU - Yano, Koji

AU - Matsumoto, Takehiro

AU - Migita, Kiyoshi

AU - Yatsuhashi, Hiroshi

AU - Ito, Masahiro

AU - Masaki, Naohiko

AU - Adachi, Hiroshi

AU - Watanabe, Yukio

AU - Nakamura, Yoko

AU - Saoshiro, Takeo

AU - Sodeyama, Takeshi

AU - Koga, Michiaki

AU - Shimoda, Shinji

AU - Ishibashi, Hiromi

PY - 2005/3

Y1 - 2005/3

N2 - Background/Aims: The presence of antibodies to the 210-kDa glycoprotein of the nuclear pore complex (gp210) is highly indicative of primary biliary cirrhosis (PBC). However, the significance of anti-gp210 antibody titers for monitoring PBC remains unresolved. Methods: We used an ELISA with a gp210 C-terminal peptide as an antigen to assess serum antibody titers in 71 patients with PBC. Results: Patients were classified into three groups: Group A in whom anti-gp210 titers were sustained at a high level, Group B in whom anti-gp210 status changed from positive to negative under ursodeoxycholic acid (UDCA) therapy, Group C in whom anti-gp210 antibodies were negative at the time of diagnosis. The rate of progression to end-stage hepatic failure was significantly higher in group A (60%) as compared to groups B (0%) and C (4.2%). The sustained antibody response to gp210 was closely associated with the severity of interface hepatitis. The significance of anti-gp210 antibody was confirmed by National Hospital Organization Study Group for Liver Disease in Japan. Conclusions: The serial quantitation of serum anti-gp210-C-terminal peptide antibodies is useful for monitoring the effect of UDCA and for the early identification of patients at high risk for end-stage hepatic failure.

AB - Background/Aims: The presence of antibodies to the 210-kDa glycoprotein of the nuclear pore complex (gp210) is highly indicative of primary biliary cirrhosis (PBC). However, the significance of anti-gp210 antibody titers for monitoring PBC remains unresolved. Methods: We used an ELISA with a gp210 C-terminal peptide as an antigen to assess serum antibody titers in 71 patients with PBC. Results: Patients were classified into three groups: Group A in whom anti-gp210 titers were sustained at a high level, Group B in whom anti-gp210 status changed from positive to negative under ursodeoxycholic acid (UDCA) therapy, Group C in whom anti-gp210 antibodies were negative at the time of diagnosis. The rate of progression to end-stage hepatic failure was significantly higher in group A (60%) as compared to groups B (0%) and C (4.2%). The sustained antibody response to gp210 was closely associated with the severity of interface hepatitis. The significance of anti-gp210 antibody was confirmed by National Hospital Organization Study Group for Liver Disease in Japan. Conclusions: The serial quantitation of serum anti-gp210-C-terminal peptide antibodies is useful for monitoring the effect of UDCA and for the early identification of patients at high risk for end-stage hepatic failure.

UR - http://www.scopus.com/inward/record.url?scp=13844289482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844289482&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2004.11.016

DO - 10.1016/j.jhep.2004.11.016

M3 - Article

C2 - 15710222

AN - SCOPUS:13844289482

VL - 42

SP - 386

EP - 392

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 3

ER -